BNP Paribas Financial Markets Has $49.94 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

BNP Paribas Financial Markets grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 93.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 580,524 shares of the company’s stock after purchasing an additional 280,541 shares during the quarter. BNP Paribas Financial Markets’ holdings in Novo Nordisk A/S were worth $49,937,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Center for Financial Planning Inc. raised its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $39,000. Finally, Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.8 %

NYSE NVO opened at $67.49 on Thursday. The stock has a market capitalization of $302.88 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 0.90 and a beta of 0.65. The business’s fifty day moving average is $70.14 and its 200-day moving average is $86.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Finally, BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating for the company. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.